<DOC>
	<DOCNO>NCT00591760</DOCNO>
	<brief_summary>The aim study investigate potential benefit correction growth hormone ( GH ) deficiency GH replacement therapy patient chronic heart failure due leave ventricular systolic dysfunction .</brief_summary>
	<brief_title>Growth Hormone Deficiency Chronic Heart Failure : A Preliminary Trial</brief_title>
	<detailed_description>To date , wide range alteration GH/IGF-1 axis describe patient chronic heart failure ( CHF ) : reduction GH level , reduction IGF-1 pattern peripheral resistance GH , particular patient severe heart failure cardiac cachexia . Unpublished experience group support concept considerable amount CHF-patients coexist Growth Hormone Deficiency ( GHD ) , define current guideline ( GH stimulation test ) . Our study hypothesis correction GH deficiency patient chronic heart failure may exert beneficial effect cardiac function remodeling , performance status quality-of-life . Since preliminary study , sample size calculation perform ; treatment effect seek leave ventricular function ( assessed cardiac MRI ) , cardiopulmonary exercise performance , clinical status , vascular reactivity , biochemistry neurohumoral marker disease ( NT-proBNP ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Heart Failure ew York Heart Association functional class II IV Left ventricular end diastolic diameter &gt; 60 mm Left ventricular ejection fraction &lt; 40 % Growth Hormone Deficiency ( define peak GH response intravenous stimulation GHRH + Arginine &lt; 9 ng/dl ) Age 1880 year Clinical stability , guidelineoriented maximal pharmacological therapy Informed consent Active Myocarditis Hypertrophic Cardiomyopathy Active endocarditis Active malignancy End stage renal disease Severe liver disease ( Child BC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Growth Hormone</keyword>
	<keyword>Anabolism</keyword>
	<keyword>Anabolic Deficiency</keyword>
	<keyword>Hormone replacement</keyword>
</DOC>